Keyphrases
Acquired Resistance
100%
Clinical Trial Data
25%
Continuous Therapy
25%
Daily Dose
25%
Dose Adjustment
25%
Dosing Schedule
100%
Epidermal Growth Factor Receptor
100%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
25%
Erlotinib
100%
High Dose
50%
Kinase Inhibitor
25%
Lung Cancer
100%
Mathematical Modeling
25%
Metabolism
25%
Metabolizer
25%
Missed Dose
50%
Mixed Population
25%
Non-small Cell Lung Cancer (NSCLC)
25%
Optimal Dosing Strategy
25%
Pharmacokinetic Parameters
25%
Pharmacokinetics
100%
Pre-emergence
25%
Resistance Development
25%
Resistance Dynamics
25%
Resistance Emergence
25%
Second-site mutation
25%
Successful Treatment
25%
T790M
50%
Tarceva
25%
Tumor Cells
25%
Via Resistance
25%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
33%
Epidermal Growth Factor Receptor
100%
Epidermal Growth Factor Receptor Kinase Inhibitor
33%
Erlotinib
100%
Lung Cancer
100%
Neoplasm
33%
Non Small Cell Lung Cancer
33%
Pharmacokinetic Parameter
33%
Pharmacokinetics
100%
Phosphotransferase Inhibitor
33%